Stocks and Investing
Stocks and Investing
Mon, October 5, 2020
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Geoff Meacham Initiated (VIR) at Strong Buy and Held Target at $55 on, Oct 5th, 2020
Geoff Meacham of B of A Securities, Initiated "Vir Biotechnology, Inc." (VIR) at Strong Buy and Held Target at $55 on, Oct 5th, 2020.
Geoff has made no other calls on VIR in the last 4 months.
There are 4 other peers that have a rating on VIR. Out of the 4 peers that are also analyzing VIR, 1 agrees with Geoff's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Anupam Rama of "JP Morgan" Upgraded from Sell to Hold and Decreased Target to $29 on, Friday, September 11th, 2020
These are the ratings of the 3 analyists that currently disagree with Geoff
- Patrick Trucchio of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $80 on, Monday, September 21st, 2020
- Paul Choi of "Goldman Sachs" Upgraded from Hold to Strong Buy and Increased Target to $54 on, Monday, September 14th, 2020
- Alan Carr of "Needham" Initiated at Strong Buy and Held Target at $62 on, Thursday, August 20th, 2020